Adamantiades-Behçet Disease (Answer: A)
The clinical presentation of recurrent oral ulcers (2 years), ocular inflammation with decreased visual acuity, erythema nodosum-like shin nodules, and bilateral arthritis in a young man is pathognomonic for Adamantiades-Behçet disease.
Clinical Reasoning
This 24-year-old man presents with the classic tetrad of Behçet's disease:
- Recurrent oral ulcers (2-year history) - the hallmark feature present in virtually all cases
- Ocular involvement - uveitis/retinal vasculitis causing pain, redness, and decreased visual acuity
- Skin manifestations - painful shin nodules consistent with erythema nodosum
- Articular involvement - bilateral ankle arthritis (3 months)
The constellation of these four features makes Behçet's disease the overwhelmingly likely diagnosis 1, 2, 3.
Why Not the Other Options?
Granulomatosis with polyangiitis (B) typically presents with upper/lower respiratory tract involvement and glomerulonephritis, not recurrent oral ulcers as a primary feature.
Polyarteritis nodosa (C) causes systemic medium-vessel vasculitis with renal, cardiac, and gastrointestinal involvement, but recurrent oral ulcers and the specific pattern of uveitis are not characteristic.
Sarcoidosis (D) can cause uveitis and erythema nodosum, but the chronic recurrent oral ulcers and this specific pattern of arthritis are not typical features.
Takayasu arteritis (E) affects large vessels (aorta and its branches) causing pulse deficits and vascular bruits, not mucocutaneous ulcers or this type of ocular disease.
Critical Management Considerations
The posterior segment eye involvement requires immediate aggressive immunosuppression 1. According to the 2018 EULAR guidelines, any patient with Behçet's and inflammatory eye disease affecting the posterior segment should receive:
- Azathioprine (Level IB evidence, Grade A recommendation)
- Cyclosporine-A (Level IB evidence, Grade A recommendation)
- Interferon-alpha (Level IIA evidence, Grade B recommendation)
- Monoclonal anti-TNF antibodies (infliximab or adalimumab) (Level IIA evidence, Grade B recommendation)
Critical pitfall: Systemic glucocorticoids should never be used alone in patients with posterior uveitis - they must be combined with systemic immunosuppressives to prevent vision loss 1.
Diagnostic Confirmation
Diagnosis is primarily clinical based on international criteria 3. While HLA-B51 positivity and pathergy testing support the diagnosis, their absence does not exclude it 3. The diagnosis rests on the clinical pattern, which this patient clearly demonstrates.